adds new forms for each of the game's weapons, new boss fight variations, and, most importantly,
I see a new Hades II update.
Among other things, The Unseen Update a kickass new song from Scylla and the Sirens. The game just keeps getting better.
There's still no v1.0 launch date, but Supergiant Games is 'starting to prepare' for the launch, according to a blog post. It's currently in early access on PC, but when it hits 1.0, it'll come out on Switch and Switch 2.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Lilly to acquire Verve in $1B bet on gene editing for heart disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease. The deal announced Tuesday offers Verve stockholders $10.50 a share, plus a contingent value right worth another $3 a share. The non-tradeable CVR would pay out if the company's experimental VERVE-102 treatment advances enough to dose a patient in a Phase 3 trial within 10 years of the transaction's closing. Verve CEO Sekar Kathiresan and other top stockholders have already agreed to tender shares that represent about 17.8% of Verve's outstanding stock and the gene editing company's board recommends that all investors agree to the tender offer, Lilly said. A second-step merger will follow if needed. The companies expect to complete the transaction in the third quarter. For Lilly, the acquisition offers greater control of a pipeline it's already invested in. The company inked a deal with Verve in 2023 to develop a product now known as VERVE-301 that's still in preclinical research. Later that year, Lilly bought other Verve opt-in rights from Beam Therapeutics that include the program for VERVE-102. 'The deal makes sense for Verve shareholders and makes sense given the exposure Lilly has to Verve's entire disclosed pipeline,' William Blair analyst Myles Minter wrote in a note to clients. Lilly is also stepping in at a time when Verve shares are undervalued, Minter said. Verve went public in 2021 with one of the largest initial offerings of the year in the biotech industry, raising almost $270 million by selling shares at $19 each. As an investment boom continued that year amid high hopes for gene therapies, Verve's shares soared above $70. But the company's lead product, VERVE-101, encountered safety concerns and Verve decided to scrap it in favor of a successor, VERVE-102, that used a different lipid nanoparticle for delivery of the treatment. That product has shown early promise. Even so, Verve shares closed at $6.27 yesterday, hurt by a general slump in investment in cell and gene therapy companies. 'Eli Lilly is getting a bargain here,' Minter wrote. Still, the 67% premium to the current share price is 'a win for Verve shareholders and the gene editing space more broadly, which has been under significant macro pressure in a difficult funding environment.' The CVR is likely to pay out, Minter said. The timeframe of 10 years shouldn't be an issue; dosing in a Phase 3 trial is more dependent on continued demonstration of safety in earlier-stage research, he wrote. The larger question for Lilly is whether patients and doctors will embrace genetic medicines for cardiovascular disease, when more traditional treatment options are readily available. Other companies have struggled in that situation. Verve counters that many patients drop off standard medications, putting themselves in danger of complications like a heart attack. The company's lead product is administered as an infusion, which also sets it apart from the complicated administration process that underlies high-profile gene editing treatments such as Vertex's Casgevy. Verve's medicine 'could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research and development, said in the company's press release. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
25 minutes ago
- Bloomberg
Coinbase Launches Stablecoin Payments Service for E-Commerce
Coinbase Global Inc. is launching a platform designed to make stablecoins a go-to payment method for online transactions, a potentially big leap forward in the mainstream adoption of cryptocurrencies meant to track the US dollar. The announcement follows the passage of landmark stablecoin legislation in the US Senate on Tuesday and comes as large retailers have expressed interest in exploring stablecoins for use as payments in online transactions, a roughly $6 trillion industry. Such use of this type of cryptocurrency threatens to circumvent card networks Visa Inc. and Mastercard Inc. and other online payment services.
Yahoo
25 minutes ago
- Yahoo
'Food Network' Star Anne Burrell's Cause of Death Will Require Autopsy
The cause of death for beloved Food Network star Anne Burrell will be determined by an autopsy. However, TMZ reported that the person who called for help reported that Burrell "went into cardiac arrest." The sad news that the popular star had died unexpectedly broke on June 17. The official cause of death for Burrell has not been determined. The Food Network has now confirmed that Burrell has died. An autopsy will be conducted to determine the cause of death, which will be investigated and determined by the medical examiner, TMZ reported, although there was no indication given that the death was anything but natural. TMZ reported that the 55-year-old star was found unresponsive on the morning of June 17 at her Brooklyn home, and paramedics responded. However, they were not able to revive her. The medical examiner "will conduct an autopsy to determine her cause of death," according to TMZ. According to TMZ, Burrell was survived by "four children, her brother, her sister, her mother, and her husband." Her fame grew on the Food Network, especially for her mentorship skills with upcoming chefs on shows like Worst Cooks in America. "Anne was a beloved wife, sister, daughter, stepmother, and friend — her smile lit up every room she entered," her family said in a statement to People. "Anne's light radiated far beyond those she knew, touching millions across the world. Though she is no longer with us, her warmth, spirit, and boundless love remain eternal." According to People, Burrell was survived by her husband Stuart Claxton. They married in 2021. He had a son Javier, People reported, adding that she is also survived by her mother, sister, and brother. The death was unexpected as it wasn't publicly known that Burrell was sick.'Food Network' Star Anne Burrell's Cause of Death Will Require Autopsy first appeared on Men's Journal on Jun 17, 2025
